ASTRAZENECA PLC |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,660 SEK | -0.67% |
|
+9.03% | +22.61% |
| 11:24am | AstraZeneca: encouraging results in lymphoma | CF |
| 11:06am | AstraZeneca notes positive trial results for Calquence treatment | AN |
| Sales 2024 * | 51.24B 559B 70.3B | Sales 2025 * | 54.8B 598B 75.19B | Capitalization | 236B 2,571B 323B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 92.95B 11.69B | Net income 2025 * | 10.2B 111B 13.99B | EV / Sales 2024 * | 4.99 x |
| Net Debt 2024 * | 19.9B 217B 27.3B | Net Debt 2025 * | 13.44B 147B 18.44B | EV / Sales 2025 * | 4.55 x |
| P/E ratio 2024 * |
28
x | P/E ratio 2025 * |
23.4
x | Employees | 89,900 |
| Yield 2024 * |
2.04% | Yield 2025 * |
2.13% | Free-Float | 96.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.67% | ||
| 1 week | +9.03% | ||
| Current month | +14.25% | ||
| 1 month | +15.28% | ||
| 3 months | +18.45% | ||
| 6 months | +18.41% | ||
| Current year | +22.61% |
1 week
1 526.00
1 695.00
1 month
1 416.501 695.00
Current year
1 261.001 695.00
1 year
1 261.001 695.00
3 years
889.501 695.00
5 years
700.001 695.00
10 years
447.501 695.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 1,660 | -0.66% | 234 748 |
| 24-04-30 | 1,672 | +0.97% | 124,463 |
| 24-04-29 | 1,656 | +0.58% | 292,246 |
| 24-04-26 | 1,646 | +0.27% | 316,442 |
| 24-04-25 | 1,642 | +6.35% | 917,143 |
Delayed Quote Nasdaq Stockholm, May 02, 2024 at 09:11 am
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-05-20
- Investor Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
152
USD
Average target price
164.3
USD
Spread / Average Target
+8.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.25% | 699B | |
| +26.72% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +4.37% | 198B | |
| -11.25% | 194B | |
| -5.59% | 154B | |
| -3.69% | 149B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
